QDEL QuidelOrtho Corp Insider Trading

CFO Busky Joseph M. bought 3,370 shares of QDEL at $23.66 on 2026-02-13, bringing holdings to 10,290 shares. Stock down -45.0% from 52-week high.

CFO Joseph M. Busky purchased 3,370 shares at $23.66, representing a 48.7% increase in his holdings to 10,290 shares. This transaction occurs as QuidelOrtho trades 45.0% below its 52-week high and has declined 31.3% over the past 30 days, following an annual revenue decline of 7.2% and negative net income of $-733.0M in the latest quarter. Notably, two other insiders also bought within the past 14 days, forming a cluster pattern. However, Busky's cross-ticker track record shows a 0.00% 90-day win rate across 2 prior buys with an average 90-day return of -9.7%, and his same-ticker history at QDEL demonstrates only 1 of 1 prior buys reaching a positive 90-day return, suggesting limited predictive value for this purchase. The timing and deteriorating fundamentals warrant observation but do not yet constitute a strong confidence signal.

CEO Blaser buys 10,540 shares of QDEL at $23.59; stock down 45.0% from 52-week high; cluster buy pattern detected.

CEO Brian J. Blaser purchased 10,540 shares at $23.59, increasing his holdings by 35.7% to 40,073 shares. The transaction occurs at a significant discount to the 52-week high of $42.89 (currently down 45.0%) and notably in a cluster pattern with 2 other insiders buying within the past 14 days. However, the company is unprofitable with net income of $-733.0M against revenue of $699.9M, and annual revenue contracted 7.2% year-over-year. Blaser's own cross-ticker track record shows a 0.00% 90-day win rate on prior buys, and his previous purchase at QDEL on 2024-12-11 returned -10.0% over 90 days, suggesting his timing at this ticker has not historically been favorable. The convergence of multiple insider purchases amid fundamental deterioration and depressed valuation warrants investor attention.

Director Strobeck purchases 10,000 shares of QDEL at $23.96; cluster buy pattern with 2 other insiders in past 14 days

Director Matthew Strobeck acquired 10,000 shares at $23.96 on 2026-02-13, increasing his holdings by 56.3% to 27.8K shares total. This transaction is part of a cluster pattern with 2 other insiders buying within the past 14 days, which reflects coordinated insider accumulation activity. The purchase occurs while the stock trades at $23.58, down -45.0% from its 52-week high of $42.89 and down -31.3% over the past 30 days, yet the company reported negative net income of $-733.0M on revenue of $699.9M and annual revenue decline of -7.2%. Across his cross-ticker open-market trading history, Strobeck's prior buys have averaged 90-day returns of +885.4% with a 66.67% win rate, providing historical context that his buying activity has been profitable, though this metric reflects his track record across multiple securities rather than QuidelOrtho-specific performance.

Director Ann D. Rhoads buys 750 QDEL shares at $28.28; stock -39.5% from 52-week high amid -7.2% revenue decline and $-733.0M annual loss.

Ann D. Rhoads, a director at QuidelOrtho, purchased 750 shares at $28.28 on 2025-12-10, increasing her holdings by 5.3% to 15,021 shares. The purchase occurs within a challenging fundamental backdrop: the company reported annual revenue decline of -7.2%, full-year net income of $-733.0M, and the stock is trading -39.5% below its 52-week high of $47.61. The 30-day price momentum (+46.0%) shows recent recovery, but the 90-day change remains negative at -3.8%. Across her broader trading history spanning multiple tickers, Rhoads' previous sales have not demonstrated consistent timing accuracy (90d well-timed rate 0.00%), suggesting this purchase should be evaluated on its standalone merits rather than as a signal of demonstrated predictive acumen specific to this company.

Director Joseph D Wilkins Jr. bought 370 shares of QDEL at $27.96; 3 other insiders also bought within 14 days as stock down -44.4% from 52-week high.

Wilkins Joseph D Jr., a Director, purchased 370 shares at $27.96 on 2025-11-26, bringing his holdings to 11,876 shares, concurrent with a cluster buy pattern—3 other insiders acquired shares within the past 14 days. The timing occurs against a backdrop of material company headwinds: QuidelOrtho reported a net loss of $-733.0M in its latest quarter against revenue of $699.9M, annual revenue growth of -7.2%, and the stock trading -44.4% below its 52-week high at the $27.96 transaction price. This multi-insider purchase activity warrants examination as to whether directors perceive value at depressed levels or are responding to operational or strategic signals not yet reflected in public filings.

CFO Busky Joseph M. buys 4,770 shares of QDEL at $26.06 (Nov 24), raising stake 221.9%; stock -40.9% from 52-week high amid -7.2% annual revenue decline and -$733.0M net loss.

Joseph M. Busky, Chief Financial Officer of QuidelOrtho Corp, purchased 4,770 shares at $26.06 on 2025-11-24, increasing his holdings from 2,150 to 6,920 shares—a 221.9% increase in position size. This comes as QDEL trades at $28.14, down 40.9% from its 52-week high of $47.61, while the company grapples with fundamental headwinds: revenue declined 7.2% year-over-year to $699.9M, and the company posted a net loss of -$733.0M over its most recent full fiscal year. Additionally, 2 other insiders purchased shares within the past 14 days, indicating a broader cluster buy pattern among company leadership. His cross-ticker track record shows 0 out of 1 prior buy decisions were well-timed at the 90-day mark, with an average 90-day return of -9.7% across his open-market history, suggesting prior purchases have not been followed by stock appreciation.

Director Mary Lake Polan buys 1,000 QDEL shares at $22.43; cluster buy pattern with 2 other insiders in 14 days

Director Mary Lake Polan purchased 1,000 shares at $22.43 on 2025-11-21, increasing her holdings to 12,640 shares. The transaction arrives in a cluster context: 2 other insiders also bought within the past 14 days. QuidelOrtho faces material headwinds—the company posted net income of $-733.0M on revenue of $699.9M in the latest quarter, with annual revenue declining -7.2% year-over-year, and the stock has fallen -44.2% from its 52-week high of $47.61 to a current price of $26.58. The insider purchase at $22.43 occurs notably below the 52-week median and represents discretionary accumulation by board leadership amid both operational distress and negative price momentum. The clustering of three insider buys within a two-week window, combined with the company's unprofitable status, warrants examination of whether management's view on valuation or operational recovery differs materially from the market's current assessment.

CEO Blaser bought 23.5K QDEL shares at $21.34, tripling stake to 29.5K amid -7.2% revenue decline, -$733.0M annual loss

Brian J. Blaser, President and CEO, purchased 23,500 shares at $21.34, increasing his total holdings by 389.5% from 6,033 to 29,533 shares. This acquisition occurs at a critical juncture for QuidelOrtho: the company reported -$733.0M net income over its most recent full fiscal year with annual revenue declining 7.2%, and the stock is currently -55.2% from its 52-week high. Blaser's prior buy at this ticker in December 2024 produced a 90-day return of -10.0%, establishing a pattern of purchases that has not delivered positive medium-term returns. The timing and magnitude of this buy—occurring as the stock has fallen 28.6% in 30 days and the company remains unprofitable—suggests the insider views current valuations as an opportunity, though his historical execution at QDEL provides no evidence of successful entry point selection.

CEO Brian Blaser purchases 6,033 shares of QDEL at $41.42 amid company's first full-year loss and -8.2% revenue decline

President and CEO Brian Blaser purchased 6,033 shares at $41.42 on 2024-12-11, establishing a position following a prior zero holding. The transaction occurs in a deteriorated financial environment: the company reported a negative net income of -$19.9M over its most recent full fiscal year and annual revenue contracted -8.2% year-over-year, with the latest quarter generating $727.1M in revenue. The stock is currently priced at $41.35, down -45.2% from its 52-week high of $75.44, and has declined -9.1% over the past 90 days despite a +3.3% 30-day rebound. A top executive's new purchase in a loss-making, declining-revenue environment warrants investor attention to understand the company's operational trajectory and management's forward outlook.

Carlyle Group (10% owner) sells all 8,260,183 shares of QDEL for $291.7M at $35.31, exiting position entirely

Carlyle Group's complete exit from QuidelOrtho—selling all 8.26M shares (100% of holdings) for $291.7M—represents a full liquidation of a significant 10% stake. This comes as QDEL trades 49.8% below its 52-week high and the company faces fundamental headwinds: negative full-year net income of $-19.9M, declining annual revenue growth of -8.2%, and quarterly net loss of $-19.9M. Carlyle's prior trades at this ticker show 4 of 5 prior sells were well-timed (stock declined after), and the cross-ticker track record reflects 80.00% well-timed rate across 20 prior sells. The combination of complete ownership stake liquidation during a period of valuation pressure and operational losses warrants close investor examination of whether this signals deteriorating confidence in the company's recovery trajectory.